He is most proud of contributing to the manufacturing of various DNA and RNA therapies and vaccines during the early years of the cell and gene therapy industry.
CONCORD, MA, November 17, 2023 /24-7PressRelease/ -- Venkata Indurthi has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
After studying genetics in high school, Dr. lndurthi was driven by the idea of how DNA could carry information that serves as the basis of life and how it could be targeted to treat diseases. He was inspired to pursue a career in the sciences, culminating in his current role as the chief scientific officer for Aldevron. Prior to obtaining his current role, he worked as the vice president and director of research and development, head of RNA operations, senior scientist, and quality control scientist. Throughout his tenure with Aldevron, Dr. lndurthi has also overseen all aspects of RNA operations, established a global research and development team, and served as the lead for the organization's mRNA manufacturing process.
During the early stages of his career, Dr. lndurthi studied the process of protein glycation, formations of advanced glycation end products, and much more as a graduate research assistant. As a research intern with the National Institute of Nutrition, he also worked on a project titled "Characterization and Functional Assessment of Collagen from Rat Tail Tendons." Dr. lndurthi began his career as an intern for Veer Chemie & Aromatics Limited.
While interning with Veer Chemie & Aromatics Limited and the National Institute of Nutrition, Dr. lndurthi earned a bachelor's degree in biotechnology from SRM University in India. Upon completing his undergraduate studies, he received a PhD in Pharmaceutical Sciences from North Dakota State University. Due to his vast breadth of knowledge, he has co-authored a number of articles, including "Calorimetric investigation of diclofenac drug binding to a panel of moderately glycated serum albumins," in the European Journal of Pharmaceutical Sciences. Along with other industry scholars, Dr. Indurthi has also contributed to the Archives of Biochemistry and Biophysics and Acta Crystallographica SectionD.
In light of his professional achievements, Dr. Indurthi earned a Doctoral Dissertation Award from the National Science Foundation and North Dakota State University Infrastructure Improvement Program. Subsequently, he won the Amgen Travel Award in 2014 and the North Dakota State University Graduate School Research Award the following year. While his career has been filled with several standout moments, he is most proud of contributing to the manufacturing of various DNA and RNA therapies and vaccines during the early years of the cell and gene therapy industry. When accounting for his success, he credits his wonderful mentors, including the co-founder of Aldevron, John Ballantyne. In the coming years, Dr. Indurthi intends to establish newer methods of biologics manufacturing in order to reduce costs and fully automate biologics manufacturing to decentralize manufacturing.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #